<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716624</url>
  </required_header>
  <id_info>
    <org_study_id>R-11-140</org_study_id>
    <secondary_id>17787</secondary_id>
    <nct_id>NCT01716624</nct_id>
  </id_info>
  <brief_title>Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder</brief_title>
  <official_title>A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy
      for children with neurogenic bladder due to spina bifida and compare results with standard
      oral oxybutynin therapy. This study hopes to demonstrate that Botulinum Toxin A can maintain
      or improve bladder storage function without side effects associated with oxybutynin use.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess urodynamic effects of intravesical botulinum toxin A injection to standard oral dose therapy</measure>
    <time_frame>Primary outcomes will be assessed at 3 and 6 months</time_frame>
    <description>The following urodynamic parameters will be measured;
Change in end fill pressure or detrusor leak point pressure (cm H2O)
Change in 20 and 30 cm H2O below volumes expressed as percentage of bladder capacity
Change in reflex volume (percentage of bladder capacity at which neurogenic detrusor overactivity starts)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calculate accrual rate</measure>
    <time_frame>Secondary outcomes will be assessed at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate cross over rate</measure>
    <time_frame>Secondary outcomes will be assessed at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate adverse event rates</measure>
    <time_frame>Secondary outcomes will be assessed at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the side effects of standard oral therapy compared to Botulinum toxin A injection</measure>
    <time_frame>Secondary outcomes will be assessed at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculate drop out rate</measure>
    <time_frame>Secondary outcomes will be assessed at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neurogenic Bladder</condition>
  <arm_group>
    <arm_group_label>Oxybutynin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin A injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>standard oral therapy</description>
    <arm_group_label>Oxybutynin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin A injection</intervention_name>
    <description>10 units/kg injected into the detrusor muscle using cystoscopy</description>
    <arm_group_label>Botulinum Toxin A injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of spina bifida and neurogenic bladder

          -  Performing clean intermittent catheterization (CIC)

          -  Taking 0.3-0.4 mg/kg/day of oxybutynin for a poorly compliant bladder

          -  Has not had previous bladder surgery

          -  Has had a urodynamic or videourodynamic study done within the last 6 months

          -  Upper motor neuron (UMN) type bladder demonstrated on last urodynamic study

          -  Urodynamic study (UDS) showing either detrusor leak point pressure &gt;40cm H2O; 30cm
             below capacity &lt;60% of total bladder capacity, 20 cm capacity &lt;70% of bladder capacity

          -  Able and willing to complete CIC Diaries and Quality of Life Questionnaires

          -  Consent and assent given to participate in trial

        Exclusion Criteria:

          -  History of lung disease, recurrent aspiration or severe neurological impairment which
             may increase risk of Botox toxicity or anesthesia

          -  Positive urine culture

          -  Known allergy to Botox
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumit Dave, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, Laweson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>London Health Sciences Centre - Victoria Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Sumit Dave</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

